{"record_key":"bluesphere-bio-inc","identifier":"bluesphere-bio-inc","external_key":"FD5C4C","title":"BlueSphere Bio, Inc.","summary":null,"url":"https://inventions.pitt.edu/startups/bluesphere-bio-inc","json_url":"https://inventions.pitt.edu/startups/bluesphere-bio-inc.json","object_key":"startups","description":"BlueSphere Bio is advancing cell therapies that direct the immune system toward cancer and other serious diseases. Built on University of Pittsburgh research and launched with UPMC Enterprises, the company uses its TCXpress platform to discover and characterize T-cell receptors for targeted treatments. [1]: https://enterprises.upmc.com/resources/insights/ceo-named-for-bluesphere-bio/\nIts lead investigational therapy, BSB-1001, is enrolling in a Phase 1 study for patients with high-risk blood cancers undergoing donor stem-cell transplantation. BlueSphere’s broader pipeline includes therapies targeting NPM1-mutated acute myeloid leukemia and recurrent respiratory papillomatosis, extending its approach to additional patient populations. [2]: https://bluespherebio.com/clinical-programs/","attributes":[{"key":"website","label":"Website","values":["https://bluespherebio.com/"]},{"key":"sector","label":"Sector","values":["Therapeutics"]},{"key":"therapeutic_areas","label":"Therapeutic Areas","values":["Immunology","Respiratory","Oncology"]},{"key":"therapeutic_indications","label":"Therapeutic Indications","values":["Leukemia"]},{"key":"funding_stage","label":"Funding Stage","values":["Series A+"]},{"key":"founders","label":"Founders","values":["Mark Shlomchik","Warren Shlomchik","Constantinos Panousis","Alex Rowe"]}],"related":[]}